

Baloxavir marboxil

04/20


ALTERNATE NAMES:

S-033188; [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate; (((12aR)-12-((11S)-7,8-Difluoro-6,11-dihydrodibenzo(b,E)thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12ahexahydro-1H-(1,4)oxazino(3,4-C)pyrido(2,1-F)(1,2,4)triazin-7-yl)oxy)methyl methyl carbonate; (((R)-12-((S)-7,8-difluoro-6,11dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate

CATALOG #:

B3014-100 100 mg B3014-500 500 ma

STRUCTURE:



MOLECULAR FORMULA: C27H23F2N3O7S

MOLECULAR WEIGHT: 5716

CAS NUMBER: 1985606-14-1

APPEARANCE: White to light yellow powder

PURITY: 99%

~30 mg/ml in DMSO (May need ultrasonication) SOLUBILITY:

DESCRIPTION: Baloxavir marboxil is a prodrug that is metabolised to the active form baloxavir acid also known as

S-033447. S-033447 is a small molecule inhibitor of the cap-dependent endonuclease of influenza A and B viruses. It shows nanomolar antiviral activity against influenza A and B viruses in vitro. In murine models of seasonal influenza and avian influenza A(H5N1) or A(H7N9), orally administered baloxavir showed a rapid reduction in pulmonary viral loads and decreased mortality. Baloxavir significantly reduced the time for alleviation of symptoms and reduced virus titres at 24 and 48 hours post-treatment at three different doses (10 mg, 20 mg and 40 mg) in a phase II study with patients experiencing

uncomplicated influenza.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

REFERENCES: 1. Hayden, F.G., Sugaya, N., Hirotsu, N. et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults

and Adolescents. N Engl J Med. 379(10):913-923 (2018).

2. Koszalka, P., Tilmanis, D., Hurt, A.C. Influenza antivirals currently in late-phase clinical trial. Influenza

Other Respir Viruses. 11(3):240-246 (2017).

RELATED PRODUCTS:

Remdesivir (Cat. No. B2997) Rilpivirine hydrochloride (Cat. No. B2427) Acyclovir (Cat. No. 2200) Cidofovir (Cat. No. B2682) Hydroxychloroquine sulfate (Cat. No. B2051)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.